Answers are grounded in this paper and cite their sources.
To assess the effect of frexalimab, a second-generation anti-CD40L monoclonal antibody, on physical and psychological impacts, and fatigue patient-reported outcome measures.
No takes yet. Share an insight, caveat, or question.
Vermersch et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: